Ladenburg Thalmann Upgrades United Therapeutics Corp. (UTHR) to Buy
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $516.56 +1.59%
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 12 | New: 26
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 12 | New: 26
Join SI Premium – FREE
Ladenburg Thalmann analyst Matthew Kaplan upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $106.00 (from $103.00).
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $79.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gartner (IT) PT Lowered to $206 at BMO Capital, adjusting estimates
- CrowdStrike (CRWD) PT Raised to $250 at Benchmark Ahead of Q2 Results
- United Therapeutics completes enrollment in PPF lung fibrosis trial
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
